207556-62-5

207556-62-5 structure

Name: NVP DPP 728 dihydrochloride
Chemical Name: 6-{[2-({2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethyl}amino)ethyl]am ino}nicotinonitrile dihydrochloride
CAS Number: 207556-62-5
Molecular Formula: C₁₅H₂₀Cl₂N₆O
Molecular Weight: 371.265
Catalog: Signaling Pathways Metabolic Enzyme/Protease Dipeptidyl Peptidase
Create Date: 2016-11-24 10:34:28
Modify Date: 2025-08-26 18:30:31
NVP-DPP728 dihydrochloride is a potent, selective and orally active dipeptidyl peptidase IV (DPP-IV) inhibitor with a Ki of 11 nM. NVP-DPP728 dihydrochloride can be used for the research of diabetes mellitus[1][2].

Name	6-{[2-({2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethyl}amino)ethyl]am ino}nicotinonitrile dihydrochloride
Synonyms	3-Pyridinecarbonitrile, 6-[[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]ethyl]amino]-, hydrochloride (1:2) 6-{[2-({2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethyl}amino)ethyl]amino}nicotinonitrile dihydrochloride 6-{[2-({2-[(2S)-2-Cyanopyrrolidin-1-yl]-2-oxoethyl}amino)ethyl]amino}nicotinonitrile dihydrochloride

Description	NVP-DPP728 dihydrochloride is a potent, selective and orally active dipeptidyl peptidase IV (DPP-IV) inhibitor with a Ki of 11 nM. NVP-DPP728 dihydrochloride can be used for the research of diabetes mellitus[1][2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Dipeptidyl Peptidase Research Areas >> Metabolic Disease
Target	Ki: 11 nM (DPP-IV) [1]
In Vivo	NVP-DPP728 inhibits DPP-IV and improves insulin secretion and glucose tolerance, probably through augmentation of the effects of endogenous GLP-1[2]. Animal Model: Obese (fa/fa) and lean (FA/?) Zucker rats[2] Dosage: 3.715 mg/kg Administration: Oral administration Result: Led to inhibition of plasma DPP-IV activity.
References	[1]. T E Hughes, et al. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry. 1999 Sep 7;38(36):11597-603. [2]. B Balkan, et al. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia. 1999 Nov;42(11):1324-31.